Biosimilars saved US health care $25.4B in 2025. This #GlobalBiosimilarsWeek, our October newsletter covers Teva’s Degevma approval, FDA’s leaner PK guidance, and new switching data, all pointing to lower costs and broader access to biologics. 🌍 hubs.li/Q04zXx2L0

🗳️ Looking ahead to Global Biosimilars Week: which biosimilars topic tops your list—access, #affordability, #biologics costs, or #healthinnovation? Vote in The Center for Biosimilars’ LinkedIn poll: hubs.li/Q04Bh-3n0

Bipartisan bills would automatically delay Medicare negotiation selection for biologics facing biosimilar competition. Meanwhile, California expands biosimilar substitution. Read more: hubs.li/Q04z_W920 #Biosimilars #Access #Affordability

🔬 Following Teva’s denosumab approval, Robert Cook, PhD, discussed biosimilars, pricing, and reliable supply—market considerations shaping #access, #affordability, and #biologics costs. Read our interview: hubs.li/Q04z_Y3h0 #HealthInnovation

Biosimilars saved US health care $25.4B in 2025, up about 26% from 2024, and $81.6B since 2015, per AAM. Real savings, but uptake still trails its potential. Affordability depends on access. 💰 #GlobalBiosimilarsWeek hubs.li/Q04zXz770

💡 Biosimilars saved US health care $25.4B in 2025, and FDA’s push to streamline PK testing could reshape how these biologics are developed. Our October newsletter breaks down what it means for #access, #affordability, #costs, and #healthinnovation. 🔗 hubs.li/Q04zP3TV0

Teva's Degevma, a denosumab biosimilar to Xgeva, is FDA-approved, completing its Xgeva/Prolia pair, as 10 companies now hold both. As competition grows, whether lower costs expand access to these #biologics is up to payers. 🦴 hubs.li/Q04z8cds0 #Biosimilars

📊 Biosimilars and generics are reshaping the cost conversation in US health care. As savings reach $496B, the market signal is clear: broader #access, #affordability, and smarter #biologics competition matter for patients and the system. Read more here: hubs.li/Q04ykn5b0

🔍 New AAM/IQVIA data shows generics and biosimilars drove $496B in 2025 savings. What do these findings signal for health innovation, biologics competition, #access, #affordability, and long-term costs? Keep an 👁️ out for our analysis here: hubs.li/Q04xZjJ70

New study: Most pediatric IBD patients maintain stable disease after switching from adalimumab originator to biosimilar. Insights may support access, affordability, and improved biologic care. #IBD #Biosimilars #Pediatrics Read more here: hubs.li/Q04xMcDD0

Analytical characterization builds trust in monoclonal antibody biosimilars, showing strong similarity to reference biologics and supporting broader access and reduced costs. hubs.li/Q04xBz3M0 #Biosimilars #Healthcare #Pharma

📊 New data on infliximab biosimilar switching in IBD suggest remission and trough levels were maintained after the switch, adding to the evidence on #biosimilars, #access, #affordability, #biologics, and #healthinnovation in care delivery. Read more here: hubs.li/Q04xv9770

💬 What do you want to see more of in the next issue of #TheBiosimilarsBulletin? We’re polling our audience on the topics shaping #biosimilars, #biologics, #access, and #affordability. Vote on our LinkedIn poll: hubs.li/Q04x7HSM0'

🔬ICYMI: Our latest #BiosimilarsBulletin covers biosimilar competition, affordability, payer dynamics, and new real-world evidence across key biologics. Catch up here: hubs.li/Q04x7yl70 #Biosimilars #Access

🧬 Real-world IBD research found that switching from originator infliximab to biosimilar CT-P13 preserved remission over 2 years, with comparable drug clearance. Biosimilars can support #healthinnovation, #access, #affordability, and #biologics costs. hubs.li/Q04w-kXM0

🔬 New IRIS Registry study: Sequential anti-VEGF step therapy may raise costs and delay care, highlighting key issues in biosimilars and access. Explore the findings: hubs.li/Q04wKqVH0 #HealthPolicy #Biosimilars

ICYMI: The latest #Biosimilars Bulletin explores how competition can expand access to biologic therapies—and what policy and market changes could mean for affordability. Read more here: hubs.ly/Q04wKp4T0

🧬 Streamlining biosimilar pathways may lower development barriers, but true access and affordability depend on more than regulation. Explore new research on costs, competition, and innovation here in the most recent Biosimilars Bulletin: hubs.li/Q04wh4W00 #HealthInnovation

✉️The latest insights from The Center for Biosimilars are arriving in your inbox tomorrow. Subscribe to the CFB LinkedIn newsletter for timely perspectives and updates on biosimilars, policy, and patient access. Not subscribed yet? Click here: hubs.li/Q04wgzSf0 #Biosimilars

📉 Biosimilar competition is reshaping the value of biologics. Edward Li of Sandoz discusses why cost-effectiveness must be reassessed to help improve access and affordability. Learn more: hubs.li/Q04w3cSn0 #Biosimilars #Healthcare